Company: CMND
Filing Date: 2025-11-26
Form Type: F-1
Source: 0001213900-25-115501
Chunk: 6

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-26
Form: F-1
Chunk 6
---
 alcohol consumption. Apart from potentially
changing people’s lives, we believe that our treatment could potentially reduce the amount currently being spent on the consequences
of AUD in the United States, Europe, India, China and other countries around the world. We also believe that our treatment may address
binge drinking. 178,000 people die every year in the United States alone due to binge drinking.

We are currently focusing our research programs
on the uses of 5-Methoxy-2-aminoindane, or MEAI, for the treatment of AUD, weight loss and metabolic disorders and as an alcohol substitute
consumer products. On the consumer side, we are developing an alcohol substitute which may offer a solution that adults can enjoy without
the extensive damage that comes with alcohol, such as higher risk to get cancer and other wide range of adverse effects on almost every
part of the body, including the brain, liver, pancreas and the immune system. We have completed a series of pre-clinical, investigational
new drug—, or IND—, enabling studies in the United States and China that are required before we can study our compound for
the first time in humans. These studies include pharmacokinetic and toxicological studies in rats and dogs in order to assess the safety
profile of our compound and characterization of the drug metabolism. We have conducted several metabolism studies designed to better understand
the way MEAI is digested in several species. In addition, we have conducted a pre-clinical animal model of AUD to characterize the effect
of MEAI on alcohol consumption. This study involved testing the effect of MEAI’s ability to curb alcohol cravings after exposing
mice to prolonged alcohol consumption over a short period, mimicking binge alcohol consumption in humans.

In February 2024 and in July 2024, we announced
that we were granted approval by the Israeli Ministry of Health and by the FDA, respectively to initiate our first-in-human Phase I/IIa
clinical trial with CMND-100 in patients suffering from AUD. Subsequently, we initiated the CM-CMND-001 clinical trial in both Israel
and the United States, including at the Yale School of Medicine’s Department of Psychiatry and Johns Hopkins University School of
Medicine. In October 2024 and December 2024, we announced that we received IRB approvals from Johns Hopkins University and Yale University,
respectively, our clinical sites, for part A of our Phase I/IIa clinical trial in the United States for treating patients